How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study
- Han Cheng (Co-first Author)
- , Shan Jiang (Co-first Author)
- , Taoran Liu
- , Boyang Li
- , Shanquan Chen
- , Ao Li
- , Hao Chen
- , Haiyin Wang*
- , Yuanyuan Gu
*Corresponding author for this work
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
4
Downloads (CityUHK Scholars)